Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

The trial testing the immune response of co-administration of GSK's blockbuster vaccines, Shingrix and Arexvy, in adults over ...

Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the ...

GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.

GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...